Skip to main content
Home
  • The Legislative Assembly meets on 07/05/2024 (01:00 PM)
    Assembly sit 07/05/2024
  • The Legislative Council meets on 07/05/2024 (01:00 PM)
    Council sit 07/05/2024
  • The Public Administration meets on 29/04/2024 (11:00 AM)
    Committee meet 29/04/2024

Parliamentary Questions


Question On Notice No. 581 asked in the Legislative Assembly on 19 October 2022 by Mr R.S. Love

Question Directed to the: Minister for Health; Mental Health
Parliament: 41 Session: 1


Question

(1) I refer to COVID-19 (Sars-COV-2) and ask:
(a) How many of the following vaccines are currently in stock in Western Australia:
(i) Moderna (Spikevax);
(ii) Pfizer (Comirnaty);
(iii) AstraZeneca (Vaxveria); and
(iv) Novavax (Nuvaxovid);
(b) Please breakdown (1a) by WA Health region;
(c) How many of the following vaccines were administered last month in WA? Please breakdown as a week-by-week comparison:
(i) Moderna (Spikevax);
(ii) Pfizer (Comirnaty);
(iii) AstraZeneca (Vaxveria); and
(iv) Novavax (Nuvaxovid);
(d) What vaccination education campaign(s) are currently underway to encourage uptake of vaccines within the under 11 year old cohort:
(i) What is the cost of those campaign(s); and
(ii) When do the campaign(s) finish;
(e) If there are no campaigns underway, are there any plans to encourage vaccination uptake before the end of 2022;
(f) With regard to wastewater testing:
(i) What is the cost to WA Health to continue wastewater testing and what has been the total cost to date;
(ii) Has there been any advice to end wastewater testing due to community prevalence of COVID-19; and
(iii) Does wastewater testing identify the subvariants of COVID-19;
(g) Does the state plan to order Omicron specific vaccine ‘Spikevax Bivalent Original/Omicron’, or mRNA-1273.214:
(i) If yes, how much of the vaccine will the State Government purchase; and
(ii) Will there be a specific vaccination education campaign to encourage uptake of the specific Omicron vaccine; and
(h) Please table any advice the Minister has received in relation to the Omicron specific vaccine ‘Spikevax Bivalent Original/Omicron’, or mRNA-1273.214?
(2) I refer to Monkeypox (MPV clade II) and ask:
(a) How much vaccine is currently in stock? Please break down by type of vaccine;
(b) How many vaccines were administered last week? Please break down by type of vaccine;
(c) How is the vaccine program currently being advertised and what is the associated cost; and
(d) Is the department undertaking or has the department requested Water Corporation test undertake wastewater testing for monkeypox? If yes, what is the cost of this program to the Department of Health?
(3) I refer to Influenza and ask:
(a) How much influenza vaccine is currently in stock? Please break down by type of vaccine;
(b) How many vaccines were administered last week? Please break down by type of vaccine; and
(c) How is the influenza vaccine program currently being advertised and what is the associated cost?

Answered on 23 November 2022

(1) (a) The WA Department of Health can only report the stock of COVID-19 vaccines used in State-run clinics as part of the WA COVID-19 Vaccination Program. The State-run program has the following stock on hand (number of vaccines):

 

(i) 500.

(ii) 125,659.

(iii) 90.

(iv) 1,074.

 

For stock of all vaccines in WA, the question should be directed to the Commonwealth.

 

    (b)

 

 

Moderna (Spikevax)

Pfizer (Comirnaty)

Paediatric Pfizer (Comirnaty)

AstraZeneca

(Vaxzevria)

Novavax (Nuvaxovid)

Country

 

2,407

1,995

 

600

Metropolitan

500

68,760

52,497

90

474

 

(c) (i) - (iv)

 

 

 

1- 7 September 2022

8 -14 September 2022

15 – 21 September 2022

22 – 28 September 2022

29 – 30 September 2022

Moderna (Spikevax)

1,610

1,445

1,106

                    636

363

Pfizer (Comirnaty)

7,052

5,774

5,267

3,289

1,746

AstraZeneca (Vaxzevria)

22

9

5

6

7

Novavax (Nuvaxovid)

239

230

231

134

89

 

(d) Continued stakeholder engagement with community organisations, schools and at targeted events to promote uptake of COVID-19 vaccinations for children; ongoing promotion via social media and website content; and a targeted email reminder campaign was issued via VaccinateWA.

 

(i) There are no additional costs for issuing VaccinateWA campaigns. COVID-19 vaccination campaigns were coordinated by the Department of the Premier and Cabinet.

 

(ii) Unpaid strategies undertaken using existing WA Health resources will continue for the remainder of this year.

 

(e) Campaigns are ongoing.

 

(f) (i) The total cost of wastewater testing to the WA Department of Health to date is $1,465,057. The projected cost for 3 months up to 31 December 2022 is $269,000.

 

(ii) No advice has been issued to end wastewater testing.

 

(iii) Wastewater testing includes testing for the presence of identified subvariants of
COVID-19.

 

(g) No.

 

(i) Not applicable.

 

(ii) No.

 

(h) None received.

 

(2) (a) 588 vials of JYNNEOS® vaccine.

 

(b) 164 doses of JYNNEOS® vaccine.

 

(c) The Department of Health support the rollout of a vaccine program targeted to protect the community against the spread of Monkeypox (MPV clade II). The total associated advertisement cost from August to December 2022 is $84,995.

 

A variety of paid and unpaid advertising strategies were utilised to promote the vaccine campaign including the following:  

 

·         Social media promotion

·         Perth International Airport digital and venue billboards

·         WA Health and HealthyWA websites

·         Social media promotion

·         Stakeholder engagement packs (digital assets and messaging)

·         Wallet cards and posters mailed out to stakeholders

·         Targeted digital display – desktop and mobile banners, including specific booking with Out In Perth publication

·         Targeted digital advertising

 

(d) No.

 

(3) (a) There are currently 468,000 doses of influenza vaccine in stock.

 

(b) 1,881 influenza vaccinations doses were administered from 10 October 2022 to 16 October 2022. The vaccine brands of these doses are recorded in AIR as follows:

 

Brand

Stock

Afluria Quad

253

bioCSL Fluvax

1

Fluad

3

Fluad Quad

162

Fluarix Tetra

371

Flucelvax Quad

5

FluQuadri

285

Fluzone High-Dose Quadrivalent

1

Generic Influenza

9

Influvac Tetra

59

Vaxigrip

11

Vaxigrip Tetra

721

 

(c) The 2022 Influenza vaccination campaign ran from April to August 2022 and the total cost was $305,000. A variety of paid and unpaid advertising strategies were utilised to promote the vaccine campaign including the following:  

 

·         Radio – metropolitan, regional and Indigenous stations

·         Digital – audio, broadcast video on demand and YouTube

·         Social media (Facebook and Instagram)

·         Outdoor of home – shopping centres, service stations, pubs, TV screens in Aboriginal community-controlled health services across WA

·         Press (state-wide) – The West Australian newspaper

·         WA Health and HealthyWA websites

·         Social media promotion

·         Direct mail out with posters, fact sheets and brochures to immunisation providers state-wide

·         Stakeholder engagement packs